List of Excipients in Branded Drug ORLADEYO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BioCryst Pharmaceuticals Inc	ORLADEYO	berotralstat hydrochloride	72769-101	CROSPOVIDONE	2035-09-09
BioCryst Pharmaceuticals Inc	ORLADEYO	berotralstat hydrochloride	72769-101	MAGNESIUM STEARATE	2035-09-09
BioCryst Pharmaceuticals Inc	ORLADEYO	berotralstat hydrochloride	72769-101	SILICON DIOXIDE	2035-09-09
BioCryst Pharmaceuticals Inc	ORLADEYO	berotralstat hydrochloride	72769-101	STARCH, CORN	2035-09-09

Orladeyo Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Orladeyo, BioCryst Pharmaceuticals’ oral berotralstat product, uses a conventional hard-gelatin capsule formulation with lactose, starch, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate. Its commercial opportunity is less likely to come from a novel excipient claim than from improved manufacturability, lactose-free alternatives, pediatric and swallowing-friendly presentations, regional excipient sourcing, and generic formulation design-arounds. Orladeyo generated approximately $348.6 million in product revenue in 2023, creating a meaningful market for formulation suppliers and competing manufacturers.[1]

What is Orladeyo and how does its formulation work?

Orladeyo is a once-daily oral kallikrein inhibitor containing 150 mg of berotralstat hydrochloride. The FDA approved it in December 2020 for routine prophylaxis to prevent attacks of hereditary angioedema, or HAE, in patients 12 years of age and older.[2]

The commercial formulation is an immediate-release hard capsule taken with food. The food requirement is relevant to excipient strategy because developers must preserve adequate exposure across meal conditions and demonstrate bioequivalence against the reference product.

Attribute	Orladeyo profile
Active ingredient	Berotralstat hydrochloride
Strength	150 mg
Dosage form	Immediate-release hard capsule
Administration	Once daily with food
Indication	Routine prevention of HAE attacks
Approved age	Adults and patients 12 years and older
Manufacturer	BioCryst Pharmaceuticals
FDA approval	December 3, 2020
Key formulation issue	Oral exposure and food-effect control
Primary commercial competitors	Takhzyro, Haegarda, Firazyr for HAE management; emerging oral kallikrein programs

Berotralstat is a small molecule rather than a biologic. Biosimilar competition therefore does not apply. The relevant future competition is from generic berotralstat products, alternative oral kallikrein inhibitors, injectable HAE prophylaxis and products that reduce treatment burden.

What excipients are used in Orladeyo capsules?

The FDA prescribing information identifies the principal inactive ingredients as lactose monohydrate, pregelatinized starch, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate. The capsule shell contains gelatin and colorants, including titanium dioxide and blue and black iron oxide pigments.[2]

Excipient or component	Likely formulation function	Commercial significance
Lactose monohydrate	Diluent and bulk-filling agent	Creates an opportunity for lactose-free redesign
Pregelatinized starch	Binder, filler and disintegration aid	Supports robust capsule filling and granulation
Croscarmellose sodium	Superdisintegrant	Important for rapid capsule-content dispersion
Colloidal silicon dioxide	Glidant and flow aid	Supports powder-flow consistency
Magnesium stearate	Lubricant	Requires control of blending time and concentration
Gelatin capsule shell	Dosage-form enclosure	Relevant to animal-origin, halal, kosher and vegetarian requirements
Titanium dioxide and iron oxides	Capsule coloration and identification	Relevant to regional regulatory and colorant restrictions

The formulation is technically conventional. That reduces manufacturing complexity but also limits the defensibility of broad excipient-based patent claims. A competing product could potentially use the same functional classes with different grades, ratios or processing conditions, subject to pharmaceutical equivalence and bioequivalence requirements.

Why does the food requirement matter for excipient selection?

Orladeyo is administered with food, and the label does not require a specific meal composition.[2] The formulation therefore has to deliver predictable exposure under the approved administration condition rather than achieve complete food independence.

Food-related development work should focus on:

• capsule disintegration after a fed meal;
• dissolution across physiologically relevant pH conditions;
• particle-size distribution of berotralstat hydrochloride;
• lubricant sensitivity;
• powder wetting and dispersion;
• robustness after storage under high humidity;
• equivalence across manufacturing sites.

The most commercially useful excipient strategy is likely to improve consistency rather than radically change release kinetics. A formulation that introduces sustained release, enteric protection or a materially different absorption profile would face a higher regulatory burden and could create clinical comparability problems.

Can excipients change berotralstat exposure?

Yes. Excipients can affect wetting, dissolution, gastric emptying, powder deagglomeration and intestinal exposure. The risk is highest where the active ingredient has limited aqueous solubility or where the formulation relies on rapid disintegration to achieve absorption.

Generic and lifecycle developers should test:

1. comparative dissolution in multiple media;
2. fed-state dissolution and dispersion;
3. capsule-opening or sprinkle performance, if pursuing an alternative administration method;
4. impurity and degradation profiles;
5. pharmacokinetic equivalence under the reference product’s fed administration condition.

A simple substitution of lactose with mannitol, microcrystalline cellulose or a co-processed filler may be commercially attractive, but it cannot be assumed to be bioequivalent without supporting data.

What commercial opportunities exist for Orladeyo excipient suppliers?

The largest near-term opportunity is supply of high-quality, validated grades rather than a single proprietary excipient.

Lactose-free and globally compatible formulations

Lactose is a recognizable differentiation point. A lactose-free berotralstat capsule could target patients with lactose intolerance, markets with stronger demand for lactose-free medicines, or procurement systems that prefer simplified excipient profiles.

Potential substitutes include:

• mannitol;
• microcrystalline cellulose;
• dibasic calcium phosphate;
• partially pregelatinized starch;
• co-processed filler-binder systems.

The substitute must preserve capsule fill weight, flow, dissolution, stability and bioequivalence. A lactose-free product could also reduce dependence on dairy-derived supply chains, although the replacement excipient may introduce new moisture, compression or segregation risks.

Vegetarian and non-gelatin capsules

The current hard capsule uses gelatin. Hydroxypropyl methylcellulose, or HPMC, and pullulan capsules could create commercial differentiation for vegetarian, vegan, halal or kosher markets.

The principal development risks are:

• altered moisture transmission;
• different shell brittleness;
• capsule-lock performance;
• compatibility with the fill blend;
• changes in dissolution under fed conditions;
• regional acceptability of colorants.

A shell conversion is more than a branding change. It requires packaging, stability and dissolution work, especially in hot and humid markets.

Pediatric and swallowing-friendly presentations

Orladeyo is approved for patients 12 years and older. A pediatric or adolescent-focused formulation could target patients who cannot reliably swallow a conventional capsule.

Potential formats include:

• capsule contents that may be opened and dispersed;
• mini-capsules;
• powder-in-bottle systems;
• oral granules;
• sprinkle formulations;
• orally disintegrating tablets.

Each format creates a different regulatory path. A sprinkle product is potentially the most practical because it may preserve the existing immediate-release profile. An oral liquid would create greater stability, taste-masking and dosing-uniformity challenges.

Taste masking is especially important if capsule contents are exposed. Berotralstat’s sensory profile, dose uniformity after dispersion and compatibility with soft food or liquid vehicles would need direct evaluation.

Co-processed excipients and direct compression

A co-processed filler-binder or flow-enhancing system could improve:

• capsule-filling speed;
• content uniformity;
• powder-flow performance;
• scale-up;
• tablet or mini-tablet conversion;
• manufacturing in facilities without wet granulation capability.

The opportunity is strongest for generic manufacturers seeking a differentiated, low-complexity process. A dry-blend process may reduce equipment and solvent requirements, but it can increase segregation risk when the active ingredient has a different particle size or density from the excipient blend.

What formulation patents could protect Orladeyo alternatives?

The most defensible formulation claims would generally focus on measurable technical characteristics rather than a standard list of excipients.

Potential claim categories include:

Claim category	Potential protection
Composition	Defined berotralstat-to-excipient ratios
Particle engineering	Specific particle-size distribution or morphology
Dissolution	Release profile within specified time limits
Stability	Reduced degradation under heat or humidity
Process	Dry blending, granulation, milling or encapsulation sequence
Capsule shell	Non-gelatin shell with defined moisture properties
Pediatric use	Dispersion or administration with approved food vehicles
Packaging	Moisture-control system linked to stability performance

A patent that claims lactose, starch, croscarmellose sodium and magnesium stearate in broad ranges would face validity and design-around pressure because those excipients are widely used in oral solid dosage forms. Stronger claims would require a demonstrated technical effect, such as improved exposure, reduced food variability, enhanced stability or a specific manufacturing advantage.

Which excipient strategy is strongest for a generic manufacturer?

A generic developer normally has three strategic options:

1. closely replicate the reference formulation using different supplier grades;
2. design around one or more excipients while maintaining pharmaceutical equivalence;
3. pursue a differentiated dosage form with a separate commercial position.

The first option minimizes development risk but may create supply-chain and patent-declaration constraints. The second offers more freedom but can increase bioequivalence risk. The third can support premium pricing but usually requires more clinical, human-factors and regulatory work.

What is the FDA regulatory status and exclusivity profile of Orladeyo?

The FDA approved Orladeyo under the new drug application pathway on December 3, 2020. Berotralstat received orphan-drug designation for HAE, giving the product seven years of orphan-drug exclusivity from approval, subject to the statutory framework.[2,3]

Regulatory protection	Relevant date
FDA approval	December 3, 2020
Five-year new chemical entity exclusivity	Generally expired December 3, 2025
Seven-year orphan-drug exclusivity	Generally extends to December 3, 2027
Pediatric exclusivity	Depends on completion and acceptance of qualifying FDA-requested studies
Patent protection	Depends on issued patents, listed claims, patent-term adjustment and any extensions

Orphan exclusivity is indication-specific and does not operate identically to patent protection. It can block approval of the same drug for the same orphan indication, but it does not eliminate all possible competition based on different products, indications or regulatory strategies.

How does patent and generic-entry risk affect excipient opportunities?

Generic entry risk is driven by both patent barriers and the technical difficulty of matching the reference product.

A Paragraph IV challenger could attack listed patents by asserting invalidity, non-infringement or unenforceability. For Orladeyo, the practical commercial questions are:

• which patents are listed in the current FDA Orange Book;
• whether listed claims cover the active ingredient, formulation, method of use or manufacturing process;
• whether a generic applicant can use a non-infringing excipient system;
• whether orphan exclusivity remains in effect for the proposed indication;
• whether litigation triggers a 30-month stay;
• whether a settlement permits an agreed launch date.

The excipient opportunity increases when formulation patents claim narrow excipient combinations or specific process parameters. A generic manufacturer can then use an alternative filler, binder, capsule shell or manufacturing process. The opportunity decreases where the reference product’s performance depends on difficult active-ingredient particle engineering or a narrow dissolution window.

Exact Orange Book patent numbers, expiry dates and litigation positions should be assessed from the current FDA listing and federal court docket because those records can change through patent listings, delistings, terminal disclaimers, settlements and regulatory events.

How does Orladeyo compare with competing HAE products?

Orladeyo’s main product-level advantage is oral once-daily dosing. Several established HAE prophylaxis products require injection, which creates a different excipient and device opportunity.

Product	Active ingredient	Administration	Excipient opportunity
Orladeyo	Berotralstat	Oral capsule once daily	Capsule shell, fill blend, pediatric and lactose-free formats
Takhzyro	Lanadelumab	Subcutaneous injection	Biologic formulation, syringe and autoinjector systems
Haegarda	C1 esterase inhibitor	Subcutaneous injection	Protein stabilization and reconstitution
Firazyr	Icatibant	Subcutaneous injection for acute treatment	Injectable formulation and device usability
Emerging oral HAE products	Varies	Oral	Direct competition in adherence and convenience

The excipient strategy for Orladeyo is therefore linked to adherence. A smaller capsule, easier swallowing, lower pill burden or broader dietary compatibility could have more commercial value than a marginal improvement in powder processing.

What licensing and partnership opportunities exist?

The most realistic licensing opportunities are adjacent to the active product rather than a broad platform license.

Potential counterparties include:

• excipient suppliers with global regulatory files;
• capsule manufacturers offering HPMC or pullulan shells;
• contract development and manufacturing organizations;
• pediatric formulation specialists;
• powder-engineering companies;
• regional generic manufacturers;
• packaging suppliers with high-barrier moisture systems.

A license could cover a proprietary co-processed excipient, a capsule-shell technology, a sprinkle formulation, a manufacturing process or a region-specific product presentation. The commercial value depends on whether the technology improves bioequivalence probability, reduces cost of goods or creates a distinct label claim.

BioCryst’s public disclosures identify Orladeyo as a core commercial product, but an excipient supplier should not assume that a technical improvement creates freedom to operate. Contract terms, formulation ownership, improvements, manufacturing rights and regulatory-data access would determine the value of any transaction.[1]

How strong is the Orladeyo formulation opportunity?

The formulation opportunity is moderate for suppliers and generic manufacturers, but weaker for a broad composition-of-matter patent strategy based only on conventional excipients.

Strong opportunities

• lactose-free capsule systems;
• vegetarian or HPMC capsule shells;
• pediatric sprinkle or mini-capsule presentations;
• improved humidity protection;
• co-processed excipients for high-speed filling;
• regional supply replacement for lactose, starch or capsule shells;
• formulations with demonstrated reduced food variability.

Weaker opportunities

• broad claims covering common filler and disintegrant combinations;
• cosmetic color changes without a clinical or manufacturing benefit;
• simple substitution of one standard lubricant for another;
• claims based only on capsule appearance;
• unvalidated claims of improved tolerability from routine excipient changes.

Key Takeaways

• Orladeyo is a once-daily 150 mg berotralstat hydrochloride hard capsule approved for HAE prophylaxis.
• Its formulation uses conventional excipients, including lactose monohydrate, pregelatinized starch, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate.
• The highest-value excipient opportunities are lactose-free formulations, non-gelatin capsules, pediatric presentations and improved moisture protection.
• Food-related exposure and dissolution are central development constraints.
• Biosimilar risk does not apply because berotralstat is a small molecule.
• Generic entry depends on the current Orange Book record, orphan exclusivity through approximately December 2027 and any listed patents or litigation settlements.
• Broad claims based on standard excipients are vulnerable to design-around strategies.
• A formulation patent is stronger when tied to a measurable technical effect, defined process or clinically relevant administration advantage.
• Orladeyo’s commercial scale supports partnership opportunities for excipient suppliers, capsule manufacturers, CDMOs and pediatric drug-delivery companies.

FAQs

Can Orladeyo be reformulated as a tablet?

Yes, but a tablet would require demonstration of comparable dissolution, exposure, stability and manufacturing performance. A tablet could reduce capsule-shell constraints but would introduce compression, hardness and disintegration requirements.

Is a lactose-free Orladeyo generic commercially attractive?

Potentially. Lactose-free positioning can differentiate a generic product, but the commercial benefit depends on payer substitution, patient demand, manufacturing cost and successful bioequivalence.

Could HPMC capsules replace gelatin capsules for berotralstat?

Yes. HPMC capsules are a technically plausible alternative, but shell moisture, dissolution, stability and regional regulatory requirements must be controlled.

Are excipient suppliers likely to obtain composition patents around Orladeyo?

They could obtain patents for narrowly defined systems with demonstrated performance advantages. Broad claims covering common pharmaceutical excipients would face substantial prior-art and design-around pressure.

Does Orladeyo have biosimilar competition?

No. Berotralstat is a small-molecule drug, so future competition would involve generic berotralstat products or alternative HAE therapies rather than biosimilars.

References

1. BioCryst Pharmaceuticals, Inc. (2024). 2023 annual report on Form 10-K. U.S. Securities and Exchange Commission.

2. U.S. Food and Drug Administration. (2020). Orladeyo prescribing information. FDA.

3. U.S. Food and Drug Administration. (2020). Orladeyo approval letter. FDA.